Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Drops By 28.1%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large decline in short interest in September. As of September 30th, there was short interest totaling 16,900 shares, a decline of 28.1% from the September 15th total of 23,500 shares. Approximately 1.4% of the shares of the stock are short sold. Based on an average trading volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days. Based on an average trading volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.4% of the shares of the stock are short sold.

Xenetic Biosciences Stock Performance

NASDAQ XBIO opened at $4.01 on Friday. The business has a fifty day moving average price of $3.69 and a 200 day moving average price of $3.30. Xenetic Biosciences has a one year low of $2.20 and a one year high of $13.93. The company has a market cap of $6.18 million, a P/E ratio of -2.01 and a beta of 2.42.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Tuesday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.19. The company had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.48 million. Xenetic Biosciences had a negative net margin of 126.08% and a negative return on equity of 54.56%. As a group, sell-side analysts predict that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Institutional Trading of Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Sachetta LLC increased its position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,259 shares of the company’s stock after acquiring an additional 4,593 shares during the quarter. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 15.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xenetic Biosciences currently has a consensus rating of “Reduce”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.